GVIRF2023

项目主任/首席调查员(最后、第一、中间)：弗里德、马丁、H 项目总结(见说明)： 世界卫生组织(世卫组织)、比尔和梅林达·盖茨基金会(比尔和梅林达·盖茨基金会)和国家 过敏和传染病研究所(NIAID)签署了一份谅解备忘录，以合作开展 全球疫苗行动计划的目标。开发GVAP是为了实现 疫苗合作十年，将免疫的全部好处扩大到所有人，无论如何 他们的出生地或居住地。2020年，GVAP被IA2030取代，其中全球 疫苗和免疫研究论坛(GVIRF)成为战略优先事项的关键组成部分7 (SP7)GVIRF是一个科学论坛，可： 1)审查SP7研发议程进展情况； 2)跟踪进展并讨论与优先疫苗研究和开发有关的障碍； 3)确定该地区研发界建议采取的行动 疫苗和免疫研究； 4)为疫苗研究和免疫界之间的联网创造机会。 第一届GVIRF于2014年3月14-16日在美国马里兰州贝塞斯达举行，第二届论坛于15-17日举行 2016年3月在南非约翰内斯堡，第三届论坛于2018年3月20日至22日在曼谷举行， 泰国。第四届论坛原定于2020年3月在大韩民国首尔举行，但不得不取消 由于新冠肺炎的流行，2021年2月举办了一个虚拟论坛。 面对面论坛定于2023年3月在大韩民国首尔举行。 该论坛由比尔和梅林达·盖茨基金会和NIAID共同主办，世卫组织提供捐助 作为对会议组织和执行的实物捐助。 相关性(请参阅说明)： IVIR-AC主席将向SAGE报告IVIR-AC会议的结论。同时，IVIR-AC 将审查SAGE会议和决定的结果，以补充和支持 塞奇。 项目/绩效网站(S)(如果需要额外空间，请使用项目/绩效网站格式页面) 项目/绩效站点主要位置 组织名称：世界卫生组织 邓斯：480997543 第一街：阿皮亚大道20号第二街： 城市：日内瓦县：州： 省：国家：瑞士邮政编码：1211 项目/表演场地国会地区： 其他项目/绩效站点位置 组织名称：待定 邓斯： 第一街：第二街： 城市：首尔县：州： 省：国家：韩国邮政编码： 项目/表演场地国会地区： PHS 398(01/18修订版获批准至2020年03/31)OMB编号0925-0001 第2页表单第2页 项目总监/首席调查员(最后、第一、中间)： 高级/关键人员。请参阅说明。根据需要使用续页，以如下所示的格式提供所需信息。 从项目主任(S)/首席调查员(S)开始。按字母顺序列出所有其他高级/关键人员，姓氏在前。 名称时代共享用户名项目上的组织角色 马丁·弗莱德·皮尔 其他重要贡献者 命名项目中的组织角色 人类胚胎干细胞否是 如果建议的项目涉及人类胚胎干细胞，请从下面的列表中列出特定细胞系(S)的注册号： Https://grants.nih.gov/stem_cells/registry/current.htm.根据需要使用续页。 如果此时不能引用某一特定行，请附上一条声明，说明将使用注册处的一行。 细胞系 PHS 398(01/18修订版获批准至2020年03/31)OMB编号0925-0001 第3页表格第2页-续 从头到尾连续地给下面的页面编号 应用程序。不要使用诸如4a、4b之类的后缀。

Program Director/Principal Investigator (Last, First, Middle): Friede, Martin, H PROJECT SUMMARY (See instructions): The World Health Organization (WHO), the Bill and Melinda Gates Foundation (BMGF) and the National Institute of Allergy and Infectious Diseases (NIAID) signed a MOU to collaborate on carrying out the objectives of the Global Vaccine Action Plan (GVAP). GVAP was developed to achieve the vision of the Decade of Vaccines of Collaboration in extending the full benefits of immunization to all people, regardless of where they were born or where they live. In 2020, GVAP was replaced by IA2030 where the Global Vaccine and Immunization Research Forum (GVIRF) became a key component of the Strategic Priorities 7 (SP7).The GVIRF serves as a scientific forum that: 1) review the SP7 R&D agenda progress; 2) track progress and discuss obstacles related to priority vaccine research and development; 3) identify actions recommended to be taken by the research and development community in the area of vaccines and immunization research, and; 4) create an opportunity for networking among the vaccine research and immunization community. The first GVIRF was held on 14-16 March 2014 in Bethesda, MD, USA, the 2nd Forum was held on 15-17 March 2016 in Johannesburg, South Africa and the 3rd Forum was held 20-22 March 2018 in Bangkok, Thailand. The 4th Forum was expected in Seoul, Republic of Korea, in March 2020, but had to be cancelled due to the Covid-19 pandemic and instead a virtual Forum took place in February 2021. An in-person forum is scheduled to take place in March 2023 in either Seoul, Republic of Korea. The Forum is co-sponsored by the Bill & Melinda Gates Foundation and NIAID, with contribution from WHO in kind for the organization and execution of the meeting. RELEVANCE (See instructions): IVIR-AC meeting conclusions will be reported by the IVIR-AC Chair to SAGE. At the same time IVIR-AC will review outcomes of SAGE meetings and decisions in order to complement and support the work of SAGE. PROJECT/PERFORMANCE SITE(S) (if additional space is needed, use Project/Performance Site Format Page) Project/Performance Site Primary Location Organizational Name: World Health Organization DUNS: 480997543 Street 1: Avenue Appia 20 Street 2: City: Geneva County: State: Province: Country: Switzerland Zip/Postal Code: 1211 Project/Performance Site Congressional Districts: Additional Project/Performance Site Location Organizational Name: TBD DUNS: Street 1: Street 2: City: Seoul County: State: Province: Country: Republic of Korea Zip/Postal Code: Project/Performance Site Congressional Districts: PHS 398 (Rev. 01/18 Approved Through 03/31/2020) OMB No. 0925-0001 Page 2 Form Page 2 Program Director/Principal Investigator (Last, First, Middle): SENIOR/KEY PERSONNEL. See instructions. Use continuation pages as needed to provide the required information in the format shown below. Start with Program Director(s)/Principal Investigator(s). List all other senior/key personnel in alphabetical order, last name first. Name eRA Commons User Name Organization Role on Project Friede, Martin WHO PI OTHER SIGNIFICANT CONTRIBUTORS Name Organization Role on Project Human Embryonic Stem Cells No Yes If the proposed project involves human embryonic stem cells, list below the registration number of the specific cell line(s) from the following list: https://grants.nih.gov/stem_cells/registry/current.htm. Use continuation pages as needed. If a specific line cannot be referenced at this time, include a statement that one from the Registry will be used. Cell Line PHS 398 (Rev. 01/18 Approved Through 03/31/2020) OMB No. 0925-0001 Page 3 Form Page 2-continued Number the following pages consecutively throughout the application. Do not use suffixes such as 4a, 4b.